Diaceutics enters into strategic alliance with KPMG to offer life sciences consulting

We are pleased to announce our strategic partnership with KPMG LLP. The alliance will combine Diaceutics’ technology, which helps pharma companies find the right patients for precision medicines, with KPMG’s life sciences consulting expertise. Together, the companies will use their knowledge and experience to offer life sciences consulting to pharma and biotech companies bring precision medicines to market.

Ryan  Keeling, Diaceutics' Chief Executive Officer, commented:

“It is great to see this partnership come to life. We have worked alongside KPMG leaders for many years with a strong admiration for their work in the precision medicine space. This alliance recognises our common goals and ambitions to shape the future of precision medicine.

Between the two organisations we have worked on many of the precision medicine therapies currently on market. This alliance will make it easier for the world’s largest and most innovative pharmaceutical and biotech organisations to get access to the best expertise and the best data available.”

Kristin Pothier, KPMG, Life Sciences Sector Leader and Global HCLS Deal Advisory and Strategy Leader, commented:

“We look forward to making our long-standing work with Diaceutics official through this new alliance. Diaceutics’ data and expertise, combined with KPMG’s data, global customer base and experience, will help clients bring precision medicines to market worldwide and improve healthcare.”

The Diaceutics x KPMG life sciences consulting partnership

Diaceutics is a leading commercialisation partner for pharma and biotech companies. Its customers include 21 of the world’s top 30 pharma companies. KPMG is a global leader in tax, audit and advisory services for healthcare and life sciences companies. Its life sciences consulting expertise supports organisations as they respond to industry changes. They work with leading technology companies, combining their expertise to deliver better solutions.

The power of more efficient diagnostic pathways to improve treatment outcomes is proven. These are, in turn, driving the shift to precision medicine across the healthcare and life sciences ecosystem. By aligning their solutions, Diaceutics and KPMG believe they can support this ecosystem. Their life sciences consulting capabilities can help companies embrace precision medicine. In doing so companies can achieve both clinical and economic returns.

The alliance will help Diaceutics and KPMG market their solutions to new and existing customers worldwide. It will also help them find new ways to work together and support the launch of life-changing precision medicines. Both teams have played key roles in launching many major companion diagnostics and the medicines they support.

Together, KPMG and Diaceutics can use real-world data to help improve healthcare decisions. By combining life sciences consulting experience they can help organisations make better decisions.